Dr Mirta Copello


Epidemic Hemorrhagic Conjunctivitis (EHC) is a conjunctival inflammation of viral etiology. It is a self-limiting condition, which follows a course in form of epidemics affecting all ages. Its main symptoms are strange body sensation, tearing, photosensitivity, general discomfort and pain.  Its critical signs are subconjunctival hemorrhages, follicular reaction and preauricular adenopathies. Also, serous secretion, chemosis, superficial punctate keratitis and palpebral ptosis are observed.

Taking into account the germicidal power of wide spectrum of OLEOZON (ozonated sunflower oil), as well as it anti-inflammatory character, the aim of this work was to evaluate this medication´s effectiveness in treating EHC. In Pedagogical Hospital ¨Dr. Salvador Allende¨ 20 patients with EHC were treated in October, 2009. Of the total, 12 received treatment with OLEOZON colirium (1 drop twice a day) and 8 made up the control group receiving conventional treatment (cold fomites, nonsteroidal anti-inflammatories, idoxuridine in colirium or Recombinant interferon alfa-2b). All patients treated with OLEOZON underwent a rapid course toward healing. After 72 hs they showed signs of great improvement, and after a week they were completely cured. None of the patients experienced complications. The control group showed a more delayed progress, mainly in patients who presented complications (3 with keratitis). OLEOZON colirium for the treatment of EHC reports very positive results for this pathology.



Retinitis Pigmentosa (RP) is characterized by bad night vision, decrease of visual field and/or acuity, with electroretinogram (ERG) diminished in amplitude and finally, non-reproducible. Taking into account some of the ozone biological effects, as improvement in the oxygen metabolism, increase in the cell energy, the immunomodulatory capacity and enhancement of the antioxidant defense system the aim of this paper is to assess ozone therapy’s efficacy in patients, treated during 20 years.

  A controlled and retrospective clinical study was performed in 56 patients with Typical Retinitis Pigmentosa (non-associated), with sample homogeneity, in age, sex and stage of the disease, and with signed informed consent. Forty patients received ozone daily, by rectal way, during 20 sessions (at a concentration of 40 mg/L and a volume of 200 mL) as only treatment, with repetition of this cycle every 6 months, and 16 received other medical treatments (control group). Results showed that, after 10 years, patients in stages I and II had a better response to ozone therapy, and this response was more lasting, with an improvement attained as of 4 months, which is the shortest time period for patients in stages II and IV. After 20 years of treatment, 50.1 % of patients improved their visual field, 31.1 % remained the same and 18 % followed the course of the disease. In respect to visual acuity, we observed that 37.5% improved, 34.9 % remained stable and 27.6 % continued the course of the disease. It is recommended to apply ozone therapy at 6months intervals to follow the course of the disease and maintain visual capacities. No side effects were observed. Ozone therapy is a good therapeutic choice in the treatment of patients with RP increasing their quality of life. 



Retinitis Pigmentosa is a disease within the group of hereditary retinal dystrophies, with great genetic heterogeneity and considered as one of the main causes of blindness in the human being. They are originated by degeneration of photoreceptor cells in retina and the main symptoms are progressive night blindness and decrease in the visual field/acuity.

  The aim of this study is to assess the efficacy of ozone therapy on patients with Retinitis Pigmentosa applying the Sensitivity to Contrast Test before and after the ozone treatment. As result, we observe the percentage of cases with SC normal values was increased after the treatment applied, basically with 12A and 18 A frequencies, at which 6 and 9 patients achieved normal values. Average values of SC showed significant changes for all spatial frequencies.